FDA OKs Genentech's Actemra to treat a rare childhood arthritis

04/17/2011 | American City Business Journals

The FDA approved Genentech's Actemra, or tocilizumab, to treat patients age 2 and older with active systemic juvenile idiopathic arthritis, or Still's disease. Actemra is given alone or with methotrexate, the agency said. The drug originally was approved early last year for adults who respond poorly to tumor necrosis factor antagonists.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA